Literature DB >> 12599189

Novel perforin mutation in a patient with hemophagocytic lymphohistiocytosis and CD45 abnormal splicing.

James McCormick1, Darren R Flower, Stephan Strobel, Diana L Wallace, Peter C L Beverley, Elma Z Tchilian.   

Abstract

Hemophagocytic lymphohistiocytosis (HLH) composes a group of rare heterogenous disorders characterized by uncontrolled accumulation and infiltration of activated T lymphocytes and macrophages. Cytotoxic T and natural killer cell activity is significantly reduced or absent in these patients. Mutations in the important mediator of lymphocyte cytotoxicity perforin were identified in a number of HLH individuals. Here we report a novel missense mutation thr435met in the conserved Ca(2+) binding domain of perforin in a patient with HLH. Prediction of the 3-dimensional structure of the thr435met perforin mutant using comparative molecular modeling indicates that the protein's ability to bind Ca(2+), and therefore its cytolytic function, would be strongly compromised. In addition, this patient exhibited abnormal CD45 splicing caused by a C77G mutation in the gene encoding CD45 (PTPRC). Our findings suggest a combined role for perforin mutation and abnormal CD45 splicing as significant contributory factors in the pathogenesis of HLH. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12599189     DOI: 10.1002/ajmg.a.10010

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  3 in total

1.  Functional assessment of perforin C2 domain mutations illustrates the critical role for calcium-dependent lipid binding in perforin cytotoxic function.

Authors:  Ramon Urrea Moreno; Juana Gil; Carmen Rodriguez-Sainz; Elena Cela; Victor LaFay; Brian Oloizia; Andrew B Herr; Janos Sumegi; Michael B Jordan; Kimberly A Risma
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

2.  Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients.

Authors:  Omer An; Attila Gursoy; Aytemiz Gurgey; Ozlem Keskin
Journal:  Protein Sci       Date:  2013-06       Impact factor: 6.725

3.  Late-onset hemophagocytic lymphohistiocytosis with neurological presentation.

Authors:  Sarah Benezech; Thierry Walzer; Emily Charrier; Damien Heidelberg; Geneviève De Saint-Basile; Yves Bertrand; Alexandre Belot
Journal:  Clin Case Rep       Date:  2017-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.